Corrigendum to A Real-World Precision Medicine Program Including the KidneyIntelX Test Effectively Changes Management Decisions and Outcomes for Patients With Early-Stage Diabetic Kidney Disease

Tokita J, Lam D, Vega A, et al. A Real-World Precision Medicine Program Including the KidneyIntelX Test Effectively Changes Management Decisions and Outcomes for Patients With Early-Stage Diabetic Kidney Disease. Journal of Primary Care & Community Health. 2024;15. doi:10.1177/21501319231223437

In the above referenced article, conflicts of interest statement has been updated. The revised information is as follows:

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MJD, TM, FF, and FT are employees of Renalytix. MK and AZ are consultants for Renalytix. SC and GN are co-founders and equity owners in RenalytixAI, Inc. Dr. Michael J Donovan, corresponding author, is a Renalytix employee and not affiliated with Mount Sinai (Email: [e-mail]).

Institutional Disclosure: KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix, Inc. The Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix, Inc.